Article metrics
PDF
Other content recommended for you
- Oestrogen receptor polymorphisms are an associated risk factor for mild cognitive impairment and Alzheimer disease in women APOE ɛ4 carriers: a case–control study
- Neurogenetics II: complex disorders
- Regional brain volume differences in symptomatic and presymptomatic carriers of familial Alzheimer's disease mutations
- Genetics and epigenetics of Alzheimer's disease
- Relation between subcortical grey matter atrophy and conversion from mild cognitive impairment to Alzheimer's disease
- The China Alzheimer Report 2022
- Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer’s disease: a focused review on recent advances
- Repurposing bromocriptine for Aβ metabolism in Alzheimer’s disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer’s disease with presenilin 1 (PSEN1) mutations
- Consensus on rapid screening for prodromal Alzheimer’s disease in China
- APOE ϵ4 increases the risk of progression from amnestic mild cognitive impairment to Alzheimer's disease among ethnic Chinese in Taiwan